News

Published on 10 May 2024 on Insider Monkey via Yahoo Finance

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript


Article preview image

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript May 9, 2024

Mersana Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all participants are in listen-only mode. There will be a question-and-answer session, at the end of this call. I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please note, this call is being recorded.

NASDAQ.MRSN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic...

Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc

On October 11, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) executed a significant...

GuruFocus.com · via Yahoo Finance 15 Oct 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) just released its quarterly report and things are lookin...

Simply Wall St. via Yahoo Finance 10 May 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript May 9, 2024 Mersana The...

Insider Monkey via Yahoo Finance 10 May 2024

Earnings call: Mersana Therapeutics reports on ADC development progress

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ: MRSN ) has provided updates on its antibody-drug...

Investing.com 1 Mar 2024

Earnings call: Mersana Therapeutics reports on ADC development progress By Investing.com

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ:MRSN) has provided updates on its antibody-drug...

Investing.com 29 Feb 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersa...

Insider Monkey via Yahoo Finance 29 Feb 2024

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday’s...

Shares of Butterfly Network, Inc. BFLY fell sharply during Thursday’s session after the company...

Benzinga 29 Feb 2024

An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued

Key Insights Mersana Therapeutics' estimated fair value is US$6.60 based on 2 Stage Free Cash Flo...

Simply Wall St. via Yahoo Finance 29 Feb 2024

Mersana shares climb as BTIG upgrades to buy with $6 target

Mersana shares climb as BTIG upgrades to buy with $6 target

Investing.com 28 Feb 2024